Page last updated: 2024-12-05

2,7-diacetylaminofluorene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,7-Diacetylaminofluorene is a fluorescent molecule that has been studied as a potential probe for bioimaging and as a model system for understanding the effects of DNA intercalation. Its synthesis involves the acetylation of 2,7-diaminofluorene, a process that introduces two acetyl groups onto the molecule. The compound has been shown to intercalate into DNA, which can lead to changes in the structure and function of DNA. This intercalation property makes it a potential target for the development of anticancer agents. 2,7-Diacetylaminofluorene is also being investigated for its potential use as a fluorescent sensor for the detection of heavy metals, such as mercury. The compound's fluorescence properties can be modulated by the presence of certain heavy metals, making it a potential tool for environmental monitoring.'

2,7-diacetylaminofluorene: has been found to induce leukemia in animals; minor descriptor (75-84); on-line search 2-ACETYLAMINOFLUORENE/AA (75-84); Index Medicus search 2-ACETYLAMINOFLUORENE/AA (80-82), FLUORENES (75-79) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9352
CHEMBL ID84749
SCHEMBL ID2962505
MeSH IDM0262629

Synonyms (71)

Synonym
CHEMBL84749
2,7-diacetaminofluorene
AKOS005443085
n,n'-9h-fluorene-2,7-diyldiacetamide
2,7-acetylaminofluorene
nsc 12282
n,n'-9h-fluorene-2,7-diylbisacetamide
n,n'-(fluoren-2,7-ylene)bis(acetylamine)
n,n'-fluoren-2,7-ylbisacetamide
2,7-bis(acetylamino)fluorene
n,n'-fluoren-2,7-ylenebisacetamide
einecs 206-153-1
acetamide, n,n'-9h-fluorene-2,7-diylbis-
2,7-fluorenylbisacetamide
brn 2815543
acetamide, n,n'-fluoren-2,7-ylenebis-
ccris 806
n,n'-2,7-fluorenylenediacetamide
n,7-fluorenylenediacetamide
n,7-fluorenylenebisacetamide
2,7-fluorenylbis(acetamide)
acetamide,n'-9h-fluorene-2,7-diylbis-
n,7-ylbis(acetamide)
acetamide,n'-fluoren-2,7-ylenebis-
304-28-9
2,7-faa
2,7-bis(acetamido)fluorene
n,7-ylenebisacetamide
wln: l b656 hhj emv1 kmv1
nsc-12282
2,7-diacetamidofluorene
n,7-ylene)bis(acetylamine)
2,7-diacetylaminofluorene
nsc12282
CBDIVE_006314
STK366707
OPREA1_230049
D0065
2,7-di(acetamido)fluorene
n-(7-acetamido-9h-fluoren-2-yl)acetamide
NCGC00249060-01
3-13-00-00508 (beilstein handbook reference)
o61ivf6hx7 ,
unii-o61ivf6hx7
dtxsid9021479 ,
cas-304-28-9
dtxcid601479
NCGC00256587-01
tox21_302864
tox21_201518
NCGC00259068-01
FT-0631919
n,n'-(9h-fluorene-2,7-diyl)diacetamide
SCHEMBL2962505
cambridge id 5135586
n,n'-2,7-fluorenylenebisacetamide
n,n'-fluorene-2,7-ylenebis(acetamide)
bis(acetylamino)fluorene, 2,7-
bis-2,7-acetylaminofluorene
n,n'-fluoren-2,7-ylenebis[acetamide]
n,n'-(2,7-fluorenylene)bis[acetamide]
n-[7-(acetylamino)-9h-fluoren-2-yl]acetamide #
n,n'-fluoren-2,7-ylbis(acetamide)
2,7-di(acetylamino)fluorene
n,n'-(fluoren-2,7-ylene)bis[acetylamine]
XBZBRCVCSVLJJZ-UHFFFAOYSA-N
AS-64515
Q27888927
T70734
A876196
CS-0316221
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency89.13970.002541.796015,848.9004AID1347397; AID1347398; AID1347399
RAR-related orphan receptor gammaMus musculus (house mouse)Potency6.72650.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency27.53910.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency27.53910.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency40.99440.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency13.81380.000221.22318,912.5098AID1259247; AID743036; AID743042; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency4.50190.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency19.82400.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency15.30960.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency12.43610.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency17.51110.000229.305416,493.5996AID1259244; AID1259248; AID743075; AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency21.81620.001024.504861.6448AID743215
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency1.53080.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency39.99770.039147.5451146.8240AID1224845
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency23.29480.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency23.29480.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID167939Carcinogenic activity on breast after oral administration of the compound1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168084Carcinogenic activity on liver after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168110Carcinogenic activity on other sites after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID167955Carcinogenic activity on ear duct after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID168098Carcinogenic activity on mixed data after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID167927Carcinogenic activity on all sites after oral administration1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Computer-assisted structure-activity studies of chemical carcinogens. Aromatic amines.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (50.00)18.7374
1990's2 (20.00)18.2507
2000's0 (0.00)29.6817
2010's2 (20.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.79 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]